G1 Therapeutics and Pepper Bio Ink Global License Agreement for Lerociclib
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, and Pepper Bio, the world’s first transomics…
Source: hitconsultant.net
Merck Digital Sciences Studio News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Merck Digital Sciences Studio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Merck Digital Sciences Studio Today - Breaking & Trending Today
G1 Therapeutics and Pepper Bio Announce Global (Excluding
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib ...
Source: globenewswire.com
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
- Pepper Bio will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib in the US, Europe, Japan, and All Other Global Markets Excluding...
Source: marketscreener.com
Vinod Khosla details how much his venture firm had on the line before Sam Altman's reinstatement at OpenAI
In 2018, Khosla Ventures wrote a $50 million check to OpenAI, though he says it was “almost impossible to diligence.”
Source: fortune.com
Drug discovery startup Pepper Bio hopes to challenge Eroom's law with new funding
While the world keeps getting better at churning semiconductors, we are still struggling to find new drugs to treat resistant diseases, and the process isn't getting cheaper. "Today, drug development still takes on average 10-15 years of R&D with a cost of production (around $2.5 billion) that has increased dramatically over the last decade despite improvements in technology: this is the concept of Eroom's law (Moore’s law spelled backwards)," deep tech VC Florian Denis wrote in a recent Medium post. While AI could help uncover new drugs, "the AI analysis...
Source: yahoo.com